Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lutetium Lu 177-EB-LM3

A radioconjugate composed of LM3, a human somatostatin receptor (SSTR) antagonist, conjugated to the albumin-binding dye Evans blue (EB) and linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against SSTR-expressing tumor cells. Upon administration, lutetium Lu 177-EB-LM3 targets and binds to SSTRs that are present on the cell membranes of many types of neuroendocrine tumors (NETs). Upon binding, SSTR-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. This agent also binds to serum albumin with its EB moiety which increases this agent’s half-life and decreases its rate of clearance. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTRs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:177Lu-EB-LM3
177Lu-Evans blue-modified LM3
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search